Latest Conference Articles

October 24th 2019, 11:23pm

Hairy Cell Leukemia Foundation Annual Conference

Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.

October 7th 2019, 2:47am

Lynn Sage Breast Cancer Symposium

Immunotherapy may finally be taking center stage in breast cancer, although much work remains to be done.

October 7th 2019, 1:53am

Lynn Sage Breast Cancer Symposium

There is an unprecedented array of therapeutic options for patients with triple-negative breast cancer, with more approaches on the horizon.

October 7th 2019, 12:35am

Lynn Sage Breast Cancer Symposium

C. Kent Osborne, MD, discusses the important take home message for physicians treating patients with HER2-positive breast cancer. Osborne says the role of HER2-positivity is complicated.

October 6th 2019, 9:26pm

Lynn Sage Breast Cancer Symposium

Hope S. Rugo, MD, discusses the latest advancements in the treatment landscape for patients with TNBC and highlights some data from clinical trials presented at the 2019 ESMO Congress.

October 6th 2019, 5:00pm

Lynn Sage Breast Cancer Symposium

Andrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.

October 6th 2019, 12:28am

Lynn Sage Breast Cancer Symposium

In breast cancer, neoadjuvant endocrine therapy shows promise in a variety of areas, including as an excellent testing platform, Ingrid A. Mayer, MD, MSCI, said in a presentation during the 2019 Lynn Sage Breast Cancer Symposium.

October 5th 2019, 11:42pm

Lynn Sage Breast Cancer Symposium

In contemporary breast cancer clinical practice, the correlation between achieving a pathologic complete response after neoadjuvant chemotherapy and significantly improved outcomes after chemotherapy has been well established. However, in a discussion at the 2019 Lynn Sage Breast Cancer Symposium, William J. Gradishar, MD, cautioned colleagues that there is more to the story when one looks at long-term data in these patients.

October 5th 2019, 11:31pm

Lynn Sage Breast Cancer Symposium

Monica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

October 5th 2019, 11:04pm

Lynn Sage Breast Cancer Symposium

Naoto Tada Ueno, MD, PhD, FACP, discusses the diagnosis and treatment of patients with inflammatory breast cancer and highlights the biggest challenges in both diagnosing and treating this patient population.

October 5th 2019, 3:00pm

Lynn Sage Breast Cancer Symposium

Tari King, MD, FACS, chief of Breast Surgery, Dana-Farber Cancer Institute, Brigham Womens Cancer Center, discusses the role of a multidisciplinary team when considering neoadjuvant chemotherapy (NAC) for patients with breast cancer.

October 5th 2019, 3:05am

Lynn Sage Breast Cancer Symposium

Jonathan B. Strauss, MD, MBA, discussed the role of hypofractionated radiotherapy in patients with breast cancer and offered advice on treatment selection.

October 5th 2019, 2:04am

Lynn Sage Breast Cancer Symposium

As more becomes known about the biology of HER2-positive early breast cancer, C. Kent Osborne, MD, says that a multipronged strategy is the best approach regarding de-escalating chemotherapy in this patient population.

October 5th 2019, 1:54am

Lynn Sage Breast Cancer Symposium

Patricia Ganz, MD, discusses the symptoms related to estrogen hormones that can cause more implications for women with breast cancer, including menopausal symptoms such as hot flashes, vaginal dryness, trouble sleeping, and fatigue.

October 4th 2019, 10:52pm

International Myeloma Society Annual Meeting

Edward A. Stadtmauer, MD, discusses the use of selinexor in patients with heavily pretreated, relapsed/refractory multiple myeloma.

October 4th 2019, 10:46pm

Lynn Sage Breast Cancer Symposium

Clinical guidelines have been necessary to help oncologists stay current in the face of rapidly evolving knowledge in HER2-positive breast cancer.

October 4th 2019, 10:28pm

Lynn Sage Breast Cancer Symposium

Kimberly Van Zee, MD, discusses the importance of preventing invasive recurrence in patients with breast cancer at the 21st Annual Lynn Sage Breast Cancer Symposium.

October 1st 2019, 7:28pm

ESMO Congress: Gynecologic Cancers

The combination of nivolumab and ipilimumab appears to have durable clinical activity in patients with recurrent or metastatic cervical cancer.

October 1st 2019, 1:56am

ESMO Congress: GU Cancers

Men who received cabazitaxel (Jevtana) as a third-line systemic agent for metastatic castration-resistant prostate cancer had a significant reduction in radiographic disease progression, leading to a significant increase in overall survival.

October 1st 2019, 12:40am

ESMO Congress: GI Cancers

Nivolumab extended overall survival compared with chemotherapy in patients with previously treated advanced esophageal squamous cell carcinoma.